Replies to post #6147 on FDA Plays

[dgras0007]

Thank you Pcrutch. Have to agree fully on BMOD, they should have known the screening controls better, lay more recruiting sites since those diagnosed with cancer are more concerned with "other" issues than to faciliate themselves for a diagnostics trials. Does make the management team look amateurish and credibility is at stake. I do like ADLS though, can not really see too much downside on this one..the contrary..the upside is huge. On ARDM I guess the data will speak volumes but it is my assumption that with the kind of partnerships they have secured there is got to be something rather promising instead. I am looking to invest in ASTM..thoughts on that one? What about HRBR and ACTC? Your input is valued.